This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

AMTD IDEA Group’s Subsidiary Secures London Stock Exchange Listing

Tipranks - Thu Dec 11, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

An update from AMTD IDEA Group ( (AMTD) ) is now available.

On December 10, 2025, The Generation Essentials Group, a subsidiary of AMTD IDEA Group, announced its successful application for a secondary listing on the London Stock Exchange. This move is expected to enhance the company’s market presence in the UK and Europe, increase share trading liquidity, and support its geographically diverse shareholder base. The listing aligns with the company’s strategic goals and reinforces its commitment to international markets.

The most recent analyst rating on (AMTD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on AMTD IDEA Group stock, see the AMTD Stock Forecast page.

Spark’s Take on AMTD Stock

According to Spark, TipRanks’ AI Analyst, AMTD is a Neutral.

AMTD IDEA Group’s strong valuation and profitability margins are offset by declining revenue and weak cash flow generation. Technical indicators suggest a bearish trend, but the stock’s low P/E ratio indicates potential undervaluation. The absence of earnings call insights and corporate events limits additional context.

To see Spark’s full report on AMTD stock, click here.

More about AMTD IDEA Group

AMTD IDEA Group operates in the financial services industry, focusing on investment banking, asset management, and strategic investments. The company has a significant presence in the UK, Europe, and internationally, aiming to reinforce its commitment to these regions.

Average Trading Volume: 333,560

Technical Sentiment Signal: Sell

Current Market Cap: $1.11B

Learn more about AMTD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.